The Clinical Value of NeuroQuant Hippocampal Volumes and Hippocampal Occupancy Scores in an Academic Medical Center Memory Clinic

NeuroQuant volumetric data proposes to assist clinical diagnoses of mild cognitive impairment (MCI) and Alzheimer disease (AD) through normative hippocampal volume measurements (HVs) and hippocampal occupancy scores (HOCs). We investigated the diagnostic utility of NeuroQuant HVs and HOCs within an...

Full description

Saved in:
Bibliographic Details
Published inCognitive and behavioral neurology Vol. 38; no. 2; p. 43
Main Authors Schaffert, Jeff, Goette, William, Nguyen, Trung, Khera, Alka, Ruchinskas, Robert
Format Journal Article
LanguageEnglish
Published United States 01.06.2025
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:NeuroQuant volumetric data proposes to assist clinical diagnoses of mild cognitive impairment (MCI) and Alzheimer disease (AD) through normative hippocampal volume measurements (HVs) and hippocampal occupancy scores (HOCs). We investigated the diagnostic utility of NeuroQuant HVs and HOCs within an academic memory disorders clinic. Participants ( n = 181) underwent neurologic examination, MRI with NeuroQuant, and neuropsychological assessment. Clinical diagnoses included subjective cognitive concerns ( n = 39), non-amnestic MCI ( n = 33), amnestic MCI ( n = 74), AD ( n = 35). Objective memory impairment ( n = 125) was determined using actuarial criteria (≥2 memory measures ≤1.5 SD below the mean) for each participant. Differences in HVs and HOCs were assessed using ANOVA and χ 2 , while Pearson correlations examined their relationship with the California Verbal Learning Test-2nd Edition (CVLT-II). Receiver operator characteristic curves were used to calculate sensitivity, specificity, predictive values, Youden's Index, and predictive summary index scores. Participants with amnestic MCI, AD, and objective memory impairment had lower HVs and HOCs and a higher frequency of hippocampal atrophy (≤5th percentile) than participants with subjective cognitive concerns, non-amnestic MCI, and no objective memory impairment ( P' s <0.05). However, the sensitivity (0.31-0.77) and specificity (0.68-0.91) of HVs and HOCs were variable for determining objective memory impairment, and correlations with the CVLT-II were modest ( r = 0.20-0.44). NeuroQuant HVs and HOCs were lower in participants with amnestic MCI, AD, and memory impairment, but had poor sensitivity and specificity to predict memory impairment, and only a modest association with measurable memory impairment. These measures should be used cautiously as supporting diagnostic tools.
ISSN:1543-3641
DOI:10.1097/WNN.0000000000000390